2162 Stock Overview
A biotechnology company, focuses on in-house discovery and development of biological therapies in the autoimmune and oncology therapeutic areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Keymed Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$40.70 |
| 52 Week High | HK$49.60 |
| 52 Week Low | HK$27.05 |
| Beta | -0.027 |
| 1 Month Change | -8.85% |
| 3 Month Change | 8.39% |
| 1 Year Change | 14.81% |
| 3 Year Change | 90.19% |
| 5 Year Change | n/a |
| Change since IPO | 54.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2162 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 0.9% | 13.0% | 1.6% |
| 1Y | 14.8% | 64.2% | 14.8% |
Return vs Industry: 2162 underperformed the Hong Kong Biotechs industry which returned 64.2% over the past year.
Return vs Market: 2162 matched the Hong Kong Market which returned 14.8% over the past year.
Price Volatility
| 2162 volatility | |
|---|---|
| 2162 Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 13.5% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in HK Market | 15.3% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2162 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2162's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 1,258 | Bo Chen | www.keymedbio.com |
Keymed Biosciences Inc., a biotechnology company, focuses on in-house discovery and development of biological therapies in the autoimmune and oncology therapeutic areas. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyposis (CRSwNP), seasonal allergic rhinitis (SAR), prurigo nodularis, and respiratory related indications. The company is also developing CM512, which is in Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of CM512 in healthy subjects and patients with moderate-to-severe atopic dermatitis; CM313, a humanized monoclonal antibody that targets CD38 in Phase I/II clinical study; CM383, a humanized monoclonal antibody for the treatment of early Alzheimer’s Disease; and CM326, a recombinant humanized monoclonal antibody targeting anti-thymic stromal lymphopoietin.
Keymed Biosciences Inc. Fundamentals Summary
| 2162 fundamental statistics | |
|---|---|
| Market cap | HK$11.22b |
| Earnings (TTM) | -HK$559.55m |
| Revenue (TTM) | HK$464.94m |
Is 2162 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2162 income statement (TTM) | |
|---|---|
| Revenue | CN¥428.12m |
| Cost of Revenue | CN¥12.20m |
| Gross Profit | CN¥415.92m |
| Other Expenses | CN¥931.17m |
| Earnings | -CN¥515.24m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.87 |
| Gross Margin | 97.15% |
| Net Profit Margin | -120.35% |
| Debt/Equity Ratio | 29.5% |
How did 2162 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/22 23:20 |
| End of Day Share Price | 2025/05/22 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Keymed Biosciences Inc. is covered by 19 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Wangbin Zhou | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |